---
schema_version: "secwatch.filing_event.v1"
accession: "0001790340-26-000059"
form_type: "8-K"
ticker: "IMRX"
cik: "0001790340"
company_name: "Immuneering Corp"
filed_at: "2026-06-01T20:51:53+00:00"
generated_at: "2026-06-01T20:55:14.587035+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Immuneering reports 17.3-month median OS in Phase 2a pancreatic trial of atebimetinib

## Summary
- In 55-patient ITT population, mOS 17.3 months (cutoff Apr 24, 2026) vs 8.5 months standard of care.
- mPFS 8.3 months; ORR 36% (18/50), DCR 82% (41/50) in response-evaluable patients.
- 84% of evaluable patients maintained or gained weight; Grade ≥3 TEAEs: Anemia 16%, Neutropenia 18%.
- Expects first patient dosed in pivotal Phase 3 (MAPKeeper 301) mid-2026; topline data mid-2028.
- Plans Phase 1b/2 trial of atebimetinib+Libtayo in NSCLC starting H2 2026; data late 2027.

## SEC filing metadata
- accession: 0001790340-26-000059
- form_type: 8-K
- ticker: IMRX
- cik: 0001790340
- company_name: Immuneering Corp
- filed_at: 2026-06-01T20:51:53+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1790340/000179034026000059/0001790340-26-000059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1790340/000179034026000059/imrx-20260601.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001790340-26-000059
- JSON: https://secwatch.observer/filing/0001790340-26-000059.json
- Plain text: https://secwatch.observer/filing/0001790340-26-000059.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.